The effect of tumor location on overall survival for pT2–4 bladder and upper tract urothelial carcinoma following radical surgery

  • Andrew W. Tam Icahn School of Medicine at Mount Sinai
  • Christine Liaw Icahn School of Medicine at Mount Sinai
  • Eric Li Icahn School of Medicine at Mount Sinai
  • Andrew B. Katims Icahn School of Medicine at Mount Sinai
  • Rollin K. Say Icahn School of Medicine at Mount Sinai
  • Zeynep Gul Icahn School of Medicine at Mount Sinai
  • Jared S. Winoker Icahn School of Medicine at Mount Sinai
  • Alberto Martini Icahn School of Medicine at Mount Sinai
  • John P. Sfakianos Icahn School of Medicine at Mount Sinai
Keywords: bladder cancer, upper tract urothelial carcinoma, survival, muscle-invasive, non-metastatic

Abstract

Introduction: Historically, staging and treatment for upper tract urothelial carcinoma were extrapolated from bladder urothelial carcinoma literature. However, embryological, genetic, and anatomical differences exist between them. We sought to explore the relationship between location of urothelial cancer and overall survival (OS).

Methods: Data was culled from the National Cancer Database from 2004–2015. Patients with pT2–pT4 treated with definitive surgery were included; those with metastatic disease or who received neoadjuvant or adjuvant treatment were excluded. Patients were stratified by tumor location and pathological stage. The primary outcome was OS. Secondary outcomes were predictors of mortality in each pT stage stratum.

Results: A total of 11 330 patients with bladder, 954 patients with ureteral, and 1943 patients with renal pelvis urothelial carcinoma were analyzed. Mean followup was 43.3, 39.4, and 41.4 months for bladder, ureteral, and renal pelvis, respectively. On univariable analysis, ureteral pT2 was associated with worse OS compared to both bladder (61.3 vs. 80.4 months, p=0.007) and renal pelvis (61.3 vs. 80.5 months, p=0.014). Renal pelvis pT3 was associated with improved OS compared to both bladder (42.5 vs. 28.6 months, p=0.003) and ureteral (42.5 vs. 25.7 months, p<0.001). Renal pelvis pT4 had decreased survival compared to bladder (11.4 vs. 17.7 months, p<0.001). On multivariable Cox regression, only renal pelvis pT3 was associated with a 20% decreased risk of mortality compared to bladder pT3 (hazard ratio 0.80, 95% confidence interval 0.72–0.88, p<0.001).

Conclusions: Renal pelvis pT3 is associated with lower mortality. Mutational and embryological differences may play a role in this disparity.

Published
2020-10-27
How to Cite
Tam, A. W., Liaw, C., Li, E., Katims, A. B., Say, R. K., Gul, Z., Winoker, J. S., Martini, A., & Sfakianos, J. P. (2020). The effect of tumor location on overall survival for pT2–4 bladder and upper tract urothelial carcinoma following radical surgery. Canadian Urological Association Journal, 15(5), E248-55. https://doi.org/10.5489/cuaj.6698
Section
Original Research